From Clinical guidelines — Diagnosis and treatment manual › Chapter 9: Genito-urinary diseases · Médecins Sans Frontières, Current online edition, 2026
MSF clinical guidance on the diagnosis and antibiotic treatment of acute bacterial prostatitis for resource-variable settings.
- Issuer
- Médecins Sans Frontières
- Edition
- Current online edition, 2026
- Audience
- Clinicians in resource-variable settings
- Evidence
- Based on NICE guideline NG110, 2018
- Reviewed
- 21 Oct 2026 · GMJ
What this guideline says
GMJ summary
This MSF clinical guideline addresses acute bacterial prostatitis, an infection most commonly caused by Escherichia coli, with other pathogens including Proteus mirabilis, Klebsiella sp, Pseudomonas aeruginosa and Enterococcus sp. The guideline emphasises recognition of characteristic clinical features: high fever with chills, cystitis symptoms (burning on urination and urinary frequency), perineal/urethral/penile or rectal pain, and urinary retention. Digital rectal examination is very painful, and laboratory findings include leukocyturia, pyuria and possible macroscopic haematuria.
Treatment centres on ciprofloxacin 500 mg orally twice daily for 14 days, with patient review at that point. If symptoms have completely resolved, treatment is stopped; if ongoing, treatment continues for a further 14 days (total 28 days). Supportive care includes adequate hydration (1.5 litres daily), fever and pain management, and surgical referral for suspected prostatic abscess.
Key points
For clinicians — doses and thresholds as stated in the guideline
- Acute prostatitis presents with high fever, chills, cystitis symptoms (burning on urination, urinary frequency), and perineal, urethral, penile or rectal pain
- <em>Escherichia coli</em> is the most common causative pathogen; others include <em>Proteus mirabilis</em>, <em>Klebsiella</em> sp, <em>Pseudomonas aeruginosa</em> and <em>Enterococcus</em> sp
- Digital rectal examination is very painful; a fluctuant mass suggests prostatic abscess
- First-line treatment: ciprofloxacin 500 mg orally twice daily for 14 days, then review
- Stop ciprofloxacin at 14 days if signs and symptoms have completely resolved; continue for a further 14 days (total 28 days) if symptoms are ongoing
- Ensure adequate hydration of 1.5 litres daily
- Refer to a surgeon if prostatic abscess is suspected
- Progression to chronic prostatitis is possible
From the guideline
Verbatim
“ciprofloxacin PO: 500 mg 2 times daily for 14 days then review the patient. Stop treatment if signs and symptoms have completely resolved.”
Editor’s perspective
Why this matters for Georgia and the region
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, Georgian Medical Journal · Chair, Public Health Institute of Georgia · WHO consultant, health and migration
As Editor-in-Chief of the Georgian Medical Journal, I recognise that acute prostatitis is commonly encountered in Georgian primary and hospital care, yet treatment duration often lacks standardisation. This MSF guideline provides a pragmatic, evidence-based approach with a 14-day review point that allows individualised treatment duration—an important principle for antimicrobial stewardship in our region. I would stress to Georgian colleagues the importance of the 14-day clinical review: stopping ciprofloxacin when symptoms have completely resolved avoids unnecessary antibiotic exposure, whilst extending to 28 days for persistent symptoms ensures adequate treatment. The main implementation consideration is ensuring adequate clinical follow-up capacity, as many patients in rural Georgia may not return for reassessment unless actively recalled, potentially leading to treatment failure or antibiotic overuse.
ORCID 0000-0001-7609-4515 · Perspective written for the GMJ Guidelines Library, 21 Oct 2026
Applicability
Georgia and the South Caucasus
This guideline is directly applicable in Georgia and the South Caucasus, where urinary tract infections including prostatitis are common presentations in primary and secondary care. Ciprofloxacin is widely available and affordable in the region, though national antimicrobial stewardship programmes should monitor local fluoroquinolone resistance patterns in E. coli and other uropathogens to ensure empirical treatment remains appropriate. Georgian clinicians working in rural settings with limited laboratory capacity will benefit from the clinical diagnostic approach, whilst those in urban centres can integrate urine microscopy and culture where available to guide therapy.
Questions this guideline answers
Quick answers
When should I stop ciprofloxacin treatment at 14 days versus continuing for 28 days?
Review the patient at 14 days. Stop treatment only if signs and symptoms have completely resolved. If any symptoms are ongoing, continue the same treatment for a further 14 days (total 28 days).
What pathogens cause acute prostatitis?
<em>Escherichia coli</em> is the most common. Other pathogens include <em>Proteus mirabilis</em>, <em>Klebsiella</em> sp, <em>Pseudomonas aeruginosa</em> and <em>Enterococcus</em> sp.
What are the key clinical features that distinguish acute prostatitis from simple cystitis?
Acute prostatitis presents with high fever and chills, perineal/urethral/penile or rectal pain, and a very painful digital rectal examination, in addition to cystitis symptoms. Urinary retention may occur.
When should I refer a patient with suspected prostatitis?
Refer to a surgeon if you suspect a prostatic abscess, indicated by a fluctuant mass on digital rectal examination.
Related on GMJ
Interconnected resources
Dictionary of Public Health
Drugs A–Z
GMJ News coverage
Quality & accreditation
- ASF Laboratory — Standard 1 — Governance & Document Control
- ASF Laboratory — Standard 6 — Pre-Examination: Specimen Pathway
- ASF Laboratory — Standard 7 — Examination: Process & Safety
- ASF Laboratory — Standard 8 — Post-Examination: Reporting & Critical Values
- ASF Hospital — Standard 4 — Care & Treatment
- ASF Hospital — Standard 7 — Governance & Management
Same guideline
- Acute pyelonephritis — MSF Clinical guidelinesChapter 9: Genito-urinary diseases
- Acute cystitis — MSF Clinical guidelinesChapter 9: Genito-urinary diseases
- Acute diarrhoea — MSF Clinical guidelinesChapter 3: Gastrointestinal disorders
- Issuer
- Médecins Sans Frontières
- Guideline
- Clinical guidelines — Diagnosis and treatment manual
- Chapter
- Chapter 9: Genito-urinary diseases
- Type
- Clinical guideline (chapter)
- Edition
- Current online edition, 2026
- Status
- Current
- Published
- 2026-10-14
- Scope
- Acute bacterial prostatitis
- Audience
- Clinicians in resource-variable settings
- Evidence
- Based on NICE guideline NG110, 2018
- Record history
- Created 21 Oct 2026 · updated 21 Oct 2026 · next check Apr 2027
Médecins Sans Frontières. Acute prostatitis. In: Clinical guidelines — Diagnosis and treatment manual. MSF; 2026 Oct 14. Chapter 9, Genito-urinary diseases.GMJ Guidelines Library records are original summaries written by the GMJ editorial team from the issuer’s published document and reviewed by a physician. They do not replace the full guideline. The document is the copyright of its issuer and is linked, not hosted. Spotted an error or a newer edition? Tell the Guidelines Desk.
Was this article helpful?
